Rewriting Alzheimer’s future together – a call to action for G7 countries
While treatments for Alzheimer’s disease have advanced dramatically, greater political will is needed to harness their potential and bring innovation to the fore. Leaders have a crucial opportunity to collaborate, change the current discourse around Alzheimer’s disease and usher in a new era – one of support, understanding and hope.
In a recent article published by POLITICO EU, Lilly highlights the urgent need for global action in the fight against Alzheimer's disease and dementia, as the number of affected individuals is expected to rise to 139 million by 2050.
Despite global commitments, health systems remain poorly equipped to adopt new diagnostic and treatment innovations, potentially leaving European patients unable to access novel tools. As G7 health ministers recently convened in Italy, Lilly has called for renewed efforts to prioritise Alzheimer’s disease as a public health emergency.
EU CAR - 2024 155
Tags in this Article:
Related articles
Revitalising clinical trials in Alzheimer's Disease in Europe: exploring ways to the...
Patricia Paukovits, Medical Affairs Advisor, Neurology at Eli Lilly, discusses the challenges faced by the pharmaceutical industry and explores ways to enhance the clinical development of Alzheimer’s disease (AD) research in Europe.
EPP says EU needs Alzheimer’s plan with concrete measures and deadlines
We understand the burden that Alzheimer’s disease (AD) places on individuals, caregivers and societies, and have dedicated more than 30 years to advancing the science of this devastating disease. We continue to encourage the recognition of initial cognitive changes caused by AD and the need to arm clinicians with resources to support early and accurate diagnosis, and for policymakers to provide investment in services and access to new therapeutics that strike at the potential causes of disease.
Building a robust diagnostic pathway for Alzheimer’s Disease
To help tackle the rising burden of Alzheimer’s disease (AD), dementia services should be structured to keep people in better health for as long as possible. Lilly is calling on clinicians, payers and policymakers to place greater emphasis on practices and programs that can increase awareness and understanding of AD, support timely action when cognitive changes are first noticed and recognize the importance of an accurate diagnosis in early symptomatic AD.